Multicenter Real‐World Analysis of Glofitamab in Relapsed/Refractory Primary CNS Lymphoma: Clinical Activity, CNS Penetration, and ctDNA Dynamics
American Journal of Hematology · 2026-07 · 101 (7) · 1763-1775
DOI: 10.1002/ajh.70342 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift American Journal of Hematology, online erschienen am 25.04.2026. Verfasst von Apeng Yang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China. Hauptthemen laut MEDLINE: Central Nervous System Neoplasms, Antibodies, Bispecific, Circulating Tumor DNA, Lymphoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Fujian Provincial Health Technology Project, Joint Funds for the Innovation of Science and Technology, Fujian Province, the Clinical Research Special Fund of the First Affiliated Hospital of Fujian Medical University.
Abstract (Originalsprache)
Therapeutic options for relapsed/refractory (R/R) primary CNS lymphoma (PCNSL) are limited, and the clinical activity and central nervous system (CNS) pharmacology of CD20 × CD3 bispecific antibody glofitamab remain poorly defined. This multicenter real‐world study evaluated the efficacy, CNS penetration, and molecular response dynamics of glofitamab in 16 adults with R/R PCNSL treated with glofitamab monotherapy. Paired plasma and cerebrospinal fluid (CSF) samples were analyzed to assess CNS drug penetration. Serial CSF circulating tumor DNA (ctDNA) profiling was performed during glofitamab monotherapy, and chimeric antigen receptor T (CAR‐T) cell kinetics were examined in patients receiving CAR‐T consolidation. Glofitamab monotherapy achieved an interim overall response rate of 75%, including 50% complete responses. Median progression‐free survival was 15.4 months, and median overall survival was not reached. In several patients, glofitamab was used as a bridge to subsequent CAR‐T and/or autologous stem cell transplantation (ASCT), which may have influenced long‐term outcomes. Glofitamab was detectable in the CSF of 60% of patients, with CSF/plasma ratios up to 0.44%. Longitudinal ctDNA analysis demonstrated that early molecular clearance was associated with radiographic response, while persistent or re‐emergent ctDNA preceded clinical progression. The safety profile of glofitamab monotherapy was manageable, with most adverse events being Grade 1–2. Two patients (11%) experienced Grade ≥ 3 neurotoxicity and recovered after corticosteroid treatment. Two additional patients developed fatal immune effector cell–associated neurotoxicity syndrome following CAR‐T consolidation. Glofitamab demonstrates early clinical activity and measurable CNS penetration in R/R PCNSL. Serial CSF ctDNA profiling may aid treatment monitoring, warranting prospective validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
- Department of Hematology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
- Department of Hematology, The Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.
- Department of Hematology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
- Department of Nuclear Medicine, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
- Department of Integrative Immunobiology, Duke University School of Medicine, Durham, USA.
ORCID-Profile: Hui Liu, Qincheng Che, Qingjiao Chen, Youwen He, Zhiyong Zeng
Förderung
- Fujian Provincial Health Technology Project
- Joint Funds for the Innovation of Science and Technology, Fujian Province
- the Clinical Research Special Fund of the First Affiliated Hospital of Fujian Medical University
- Natural Science Foundation of Fujian Province
Zitieren
APA
Yang, A., Dong, J., Deng, X., Liu, H., Chen, Z., Lin, J., Che, Q., Lin, Q., Lai, G., Zheng, M., Zheng, X., Chen, Q., Wang, J., Chen, J., He, Y., & Zeng, Z. (2026). Multicenter Real‐World Analysis of Glofitamab in Relapsed/Refractory Primary CNS Lymphoma: Clinical Activity, CNS Penetration, and ctDNA Dynamics. American Journal of Hematology, 101(7), 1763-1775. https://doi.org/10.1002/ajh.70342
Vancouver
Yang A, Dong J, Deng X, Liu H, Chen Z, Lin J, et al. Multicenter Real‐World Analysis of Glofitamab in Relapsed/Refractory Primary CNS Lymphoma: Clinical Activity, CNS Penetration, and ctDNA Dynamics. American Journal of Hematology. 2026;101(7):1763-1775. doi:10.1002/ajh.70342
BibTeX
@article{Yang2026,
author = {Yang, Apeng and Dong, Jinfeng and Deng, Xiaofang and Liu, Hui and Chen, Zhenying and Lin, Junfang and Che, Qincheng and Lin, Qiaoxian and Lai, Guilan and Zheng, Meihong and Zheng, Xiaoqiang and Chen, Qingjiao and Wang, Jizhen and Chen, Junmin and He, Youwen and Zeng, Zhiyong},
title = {Multicenter Real‐World Analysis of Glofitamab in Relapsed/Refractory Primary CNS Lymphoma: Clinical Activity, CNS Penetration, and ctDNA Dynamics},
journal = {American Journal of Hematology},
year = {2026},
volume = {101},
number = {7},
pages = {1763--1775},
doi = {10.1002/ajh.70342}
}
EUVIMED